B+
Bull case
25%
Probability
Target price
$48.00
Analysis reference price unavailable
Analysis 2026-08-14 · RankAlpha Sentiment Codex
MLYS
Mineralys TherapeuticsCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
50%
Probability
Target price
$30.00
Analysis reference price unavailable
Analysis 2026-08-14 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$17.00
Analysis reference price unavailable
Analysis 2026-08-14 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-14
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+70.2
Score
AI commentary
The official SEC Exhibit 99.1 confirms the Q2 operating and financing developments, but the earnings follow-up still lacks verified consensus surprise data, guidance changes, and post-print analyst revisions. Secondary historical pricing shows the first full session after the after-close release closed at $27.05 versus $27.33 on August 11, a 1.02% decline with higher volume, indicating a modestly negative immediate reaction rather than strong confirmation ([StockAnalysis historical data](https://stockanalysis.com/stocks/mlys/history/)). Social coverage is unavailable, so confidence remains tentative.
RankAlpha Sentiment Codex - 2026-08-14
Open post-earnings memoEvidence flagged
later post-earnings follow-up lacks concrete company-source and analyst/market reaction evidence
Impact
tentative
Confidence
-
AI events
2026-08-11eventQ2 release: financing and commercial-readiness updateMedium impact
The official Q2 filing reports a $150.0 million follow-on offering, an initial $100.0 million draw under a potential $500.0 million term-loan facility, elimination of Tanabe royalty obligations, and commercial preparations remaining on-track ahead of the PDUFA date. EPS/revenue surprise versus consensus was not available [#SEC-8K-2026-08-11].
2026-12-22eventFDA PDUFA decision for lorundrostatHigh impact
The FDA continues reviewing lorundrostat for hypertension with a December 22, 2026 PDUFA target date. The decision is the principal binary catalyst, and approval is not assured [#SEC-8K-2026-08-11].
2027-08-14catalystConditional commercial launch executionHigh impact
Mineralys reports identified priority geographies, ongoing engagement with hypertension experts and payers, and plans to establish its sales organization before the anticipated PDUFA date. Realized value remains dependent on approval, reimbursement, uptake, and execution [#SEC-8K-2026-08-11].
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-14 • Updated nightlySource: Internal modelMethodology